Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1Phase 1 1

Status

Terminated 2Completed 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

CNS 4Breast 4Dermatologic 3Thoracic 2Sarcoma 2Other solid neoplasm 2Gastrointestinal 2Genitourinary 1

Conditions

Melanoma 3Pancreatic Neoplasms 1Lung Neoplasms 1Breast Neoplasms 1

Interventions

pembrolizumab 339Nivolumab 305Ipilimumab 274Cyclophosphamide 195aldesleukin 148Interleukin-2 110fludarabine phosphate 107trametinib 85Temozolomide 83fludarabine 81Dacarbazine 81dabrafenib 77Radiotherapy 75Biopsy 75Vemurafenib 71Imiquimod 53Bevacizumab 51sargramostim 50Magnetic Resonance Spectroscopy 50Radiosurgery 49Peripheral Blood Stem Cell Transplantation 49Paclitaxel 49Aminolevulinic Acid 49binimetinib 48Specimen Handling 48Carboplatin 48Blood Specimen Collection 47cemiplimab 46Cisplatin 453-ingenyl angelate 45

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
1-methyltryptophan × Dermatologic × Clear all
NCT02073123 2026-05-29

Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma

Lumos Pharma

Phase 1/2 Completed
131 enrolled 23 charts
Dermatologic

Melanoma

NCT03301636 2022-09-27

NLG2107

Lumos Pharma

Phase 2 Terminated
21 enrolled 11 charts
Dermatologic

Melanoma

NCT00739609 2020-05-28

D-1MT

Lumos Pharma

Phase 1 Terminated
17 enrolled
BreastDermatologicGastrointestinalThoracic

Breast Neoplasms, Lung Neoplasms, Melanoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡